A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 11 1 2020
medline: 24 6 2020
entrez: 11 1 2020
Statut: ppublish

Résumé

To validate the observed/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals. This was a retrospective population-based study of stage I-IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals. The study population included 30,051 patients who were treated at 426 hospitals: low observed/expected ratio (n=304) 23.5% of cases; intermediate observed/expected ratio (n=92) 57.8% of cases; and high observed/expected ratio (n=30) 18.7% of cases. Hospitals with high observed/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed/expected ratios (P<.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed/expected ratios to 48.1 months for hospitals with low observed/expected ratios (P<.001). Treatment at a hospital with a high observed/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01-1.11, P<.05) and low (HR 1.10, 95% CI 1.04-1.16, P<.001) observed/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78-0.93, P<.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68-0.81 P<.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83-0.99, P<.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36-0.46, P<.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed/expected ratio. Ovarian cancer care at a hospital with a high observed/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed/expected ratio hospital classification is a potential mechanism for expanded access to expert care.

Identifiants

pubmed: 31923082
doi: 10.1097/AOG.0000000000003665
pmc: PMC7012338
pii: 00006250-202002000-00012
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

328-339

Subventions

Organisme : NIMHD NIH HHS
ID : R01 MD009697
Pays : United States

Références

Gynecol Oncol. 2015 Jul;138(1):121-7
pubmed: 25913132
J Clin Oncol. 2005 Dec 20;23(36):9079-88
pubmed: 16301598
Gynecol Oncol. 2014 May;133(2):142-6
pubmed: 24517876
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49
pubmed: 23138163
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Gynecol Oncol. 2011 Aug;122(2):319-23
pubmed: 21632099
Eur J Surg Oncol. 2015 Apr;41(4):585-91
pubmed: 25624160
Obstet Gynecol. 2013 Jun;121(6):1226-1234
pubmed: 23812456
Oncology (Williston Park). 1997 Nov;11(11A):95-105
pubmed: 9430180
South Med J. 2018 Jun;111(6):333-341
pubmed: 29863220
Cancer. 2010 Oct 15;116(20):4840-8
pubmed: 20578182
Environ Res. 2017 Jul;156:388-393
pubmed: 28395243
Gynecol Oncol. 2015 Dec;139(3):495-9
pubmed: 26387962
Cancer. 2007 May 15;109(10):2031-42
pubmed: 17420977
Gynecol Oncol. 2013 Oct;131(1):158-62
pubmed: 23872110
Med Care. 2016 Sep;54(9):e55-64
pubmed: 24638121
N Engl J Med. 2011 Jun 2;364(22):2128-37
pubmed: 21631325
Gynecol Oncol. 2008 Nov;111(2):173-8
pubmed: 18823649
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Obstet Gynecol. 2015 Apr;125(4):833-842
pubmed: 25751200
Gynecol Oncol. 2006 Nov;103(2):383-90
pubmed: 17005244
Gynecol Oncol. 2010 Sep;118(3):262-7
pubmed: 20573392
Ann Surg Oncol. 2016 Mar;23(3):989-93
pubmed: 26511267
Am J Obstet Gynecol. 2015 Apr;212(4):468.e1-9
pubmed: 25448522
Gynecol Oncol. 2013 Apr;129(1):258-64
pubmed: 23266352
Cancer. 2009 Sep 15;115(18):4210-7
pubmed: 19536873
Cancer. 1997 Aug 15;80(4):816-26
pubmed: 9264366
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32
pubmed: 23539755
Gynecol Oncol. 2014 Feb;132(2):403-10
pubmed: 24361578
Gynecol Oncol. 2014 Jul;134(1):60-7
pubmed: 24680770
J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209
pubmed: 24142821
Gynecol Oncol. 2016 Aug;142(2):211-6
pubmed: 27238084
Arch Pathol Lab Med. 1997 Nov;121(11):1145-50
pubmed: 9372740
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110
Obstet Gynecol. 2017 Sep;130(3):545-553
pubmed: 28796677
Obstet Gynecol. 2003 Sep;102(3):499-505
pubmed: 12962932
Gynecol Oncol. 2012 Apr;125(1):19-24
pubmed: 22108636
Milbank Mem Fund Q. 1966 Jul;44(3):Suppl:166-206
pubmed: 5338568

Auteurs

Robert E Bristow (RE)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, School of Medicine, and the Chao Family Comprehensive Cancer Center, Orange, and the Department of Medicine, University of California, Irvine, School of Medicine, and the Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, Irvine, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH